Yangtze Securities Underwriting and Sponsorship Co., Ltd.
Verification Opinion on the Self-Inspection Report of Trading of Relevant Parties in the Transaction of Wuhan Mindong Biotechnology Co., Ltd.
Wuhan Mindong Biotechnology Co., Ltd. (hereinafter referred to as "Mindong Biotechnology" or "the Company") intends to acquire 100% equity of Wuhan Bikai'er Rescue Products Co., Ltd. (hereinafter referred to as "Bikai'er") from Blue Sail Medical Co., Ltd. by means of cash payment (hereinafter referred to as "this Transaction").
In accordance with the "Administrative Measures for Major Asset Restructuring of Listed Companies" (hereinafter referred to as the "Restructuring Measures"), "Format Rules for Information Disclosure of Securities Issuing Companies No. 26 - Major Asset Restructuring of Listed Companies" (hereinafter referred to as the "Format Rules No. 26"), "Supervision Guidelines for Listed Companies No. 5 - Management System for Registration of Insiders of Listed Companies" and "Supervision and Administration Rules for Listed Companies No. 1 - Listed Companies" (hereinafter referred to as "Supervision Rules No. 1"), "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 8 - Major Asset Restructuring" (hereinafter referred to as the "Self-Regulatory Supervision Guidelines No. 8"), Yangtze Securities Underwriting and Sponsorship Co., Ltd. (hereinafter referred to as "Yangtze Securities Sponsorship" or "Independent Financial Advisor"), as the independent financial advisor for this Transaction, has verified the self-inspection report on the trading of stocks by relevant parties in this Transaction. The specific situation is as follows:
I. Verification Period for Trading of Stocks by Relevant Parties in this Transaction
In accordance with the relevant provisions of the "Restructuring Measures", "Format Rules No. 26", "Supervision Rules No. 1", and "Self-Regulatory Supervision Guidelines No. 8", the self-inspection period for trading of stocks by relevant parties in this Transaction is from 6 months prior to the Company's first disclosure of the restructuring matter to the disclosure of the restructuring report, i.e., from June 30, 2025, to June 29, 2026 (hereinafter referred to as the "Self-Inspection Period" or "Verification Period").
II. Scope of Verification for Trading of Stocks by Relevant Parties in this Transaction
The scope of verification for trading of stocks by relevant parties in this Transaction includes:
-
The Company and its directors, senior management, and relevant informed personnel;
-
The counterparty to the transaction and its directors, senior management, and relevant informed personnel;
-
The controlling shareholder of the Company and its directors, senior management, and relevant informed personnel;
-
The target company and its directors, supervisors, senior management, and relevant informed personnel;
-
Relevant intermediary agencies providing services for this Transaction and their responsible personnel;
-
Other legal persons and natural persons who are aware of the insider information of this Transaction;
-
Immediate family members of the above-mentioned natural persons, including spouses, parents, and adult children.
III. Trading of Stocks by Relevant Personnel and Institutions in this Transaction
According to the "Inquiry Certificate of Shareholding and Share Change of Information Disclosure Obligors" and "Shareholder Share Change Detailed List" issued by China Securities Depository and Clearing Corporation Limited Shenzhen Branch, and the self-inspection reports, relevant explanations, and commitments provided by the relevant insider information subjects, and after interviews, the trading of stocks of the Company by relevant parties within the scope of verification during the self-inspection period is as follows:
(I) Trading of Mindong Biotechnology Stocks by Natural Persons
During the verification period, the trading of Mindong Biotechnology stocks by relevant natural persons is as follows: